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Context: Dyslipidemias represent a spectrum of lipid disorders that are important risk factors for cardiovascular disease. In addition, elevated
triglycerides are known to be associated with pancreatitis. Though less clear, it is possible that dyslipidemias may also contribute to risk for venous
thromboembolism (VTE). Ethinyl estradiol and progestogen, contained within combined hormonal contraception, are known to impact lipid metabolism.
Objectives: To evaluate from the literature whether use of combined hormonal contraception (CHC), including combined oral contraception
(COC) pills, transdermal patch, vaginal ring or injectables, modifies the relative risk of acute myocardial infarction (MI), stroke, VTE or
pancreatitis among women with known dyslipidemias and to determine if existing lipid abnormalities worsen with CHC use.
Methods: PubMed and the Cochrane Library databases were searched for all articles in all languages published between inception and
September 2014 relevant to dyslipidemia, CHC use and serious adverse events (MI, stroke, VTE or pancreatitis). The quality of each
individual study was assessed using the system for grading evidence developed by the United States Preventive Services Task Force.
Results: From 306 articles identified by our search strategy, 3 articles met inclusion criteria. In a poor-quality case–control study, women with
hypercholesterolemia but noCOCuse had an increased risk ofMI (adjusted odds ratio [adj OR] 3.3, 95% confidence interval [CI] 1.6–6.8), as didwomen
who used COCs but did not have hypercholesterolemia (adj OR 2.0, 95% CI 1.4–2.8), compared with non-COC users without hypercholesterolemia;
women with both COC use and hypercholesterolemia had an adjusted OR of 24.7 (95%CI 5.6–108.5) compared with women with neither risk factor. A
poor-quality cohort study examinedCOCusers and reported thatwomenwith dyslipidemia had increased risk forVTE [crude risk ratio (RR) 1.39, 95%CI
1.04–1.85] and transient ischemic attacks or cerebrovascular accidents (CVAs) (RR 1.76, 95% CI 1.51–2.06) compared to those without dyslipidemia.
Another poor-quality cohort study provided direct evidence on changes in lipid levels among COC users with dyslipidemia. A minority of women with
elevated total cholesterol or triglyceride levels at baseline showed normal results (25% and 28%, respectively) after 6 cycles of COC use. No evidence
regarding risks associated with use of other CHC methods was identified. No evidence was identified for the outcome of pancreatitis.
Conclusion: Limited data from poor-quality observational studies suggest that women with known dyslipidemias using CHC may be at
increased risk for MI and may experience a minimal increase in risk for CVA or VTE. No evidence was identified on risk for pancreatitis in
this context. The impact of CHC exposure on the status of lipid abnormalities over time, an intermediate marker for disease, is also unclear.
Given the significant limitations of this body of evidence, the importance of access to effective contraception and theoretical concerns raised
about the use of CHCs by women with known dyslipidemias, additional rigorous studies are needed to best estimate true associations.
Contraceptive decision making should include consideration of both the known and theoretical risks of a given CHC method, safety and
acceptability of alternative contraceptive methods, and risks associated with unintended pregnancy.
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Dyslipidemias represent a spectrum of abnormalities
resulting from aberrant lipid metabolism leading to excessive
entry of lipoproteins into the bloodstream, an impairment in
their removal, or both [1]. Dyslipidemias can be genetic in
origin and/or result from or be exacerbated by a variety of
secondary factors including lifestyle, other medical conditions
and use of certain medications. Elevations in total cholesterol,
low-density lipoprotein (LDL) and triglycerides, as well as
depressions in high-density lipoprotein (HDL) are important
risk factors for cardiovascular disease [2,3]. In addition, lipid
disorders have been associated with risk for venous thrombo-
embolism (VTE), and extremely elevated triglyceride levels are
a well-established etiology for pancreatitis [4,5].
Ethinyl estradiol (EE) and progestogens contained in
combined hormonal contraception (CHC), including pills,
transdermal patch, vaginal ring or injectables, impact lipid
metabolism. Typically, EE enhances removal of LDL and
increases levels of HDL and triglycerides; progestogens exert
an opposite effect [6]. We have undertaken this systematic
review to examine whether use of CHC among women with
known dyslipidemias increases risk for acute myocardial
infarction (MI), stroke, VTE or pancreatitis compared with
nonuse of hormonal contraceptives. Because changes in lipid
levels are an important surrogate marker for our clinical
outcomes of interest, we also evaluated whether CHC use
among women with dyslipidemia increases risk for worsening
of lipid abnormalities.2. Materials and methods
2.1. Evidence retrieval
We searched the PubMed and Cochrane Library databases
for all articles (in all languages) published in peer-reviewed
journals from inception through September 2014, for evidence
relating to acute MI, stroke, VTE, pancreatitis, CHC use and
dyslipidemia. The search strategy can be found in Appendix A.
We hand-searched reference lists from articles identified by the
search, aswell as any key reviews, to identify additional articles.
We did not attempt to identify unpublished articles or abstracts
from scientific conferences or contact any individual authors.
2.2. Study selection
We reviewed titles and abstracts and the full article, when
necessary, to identify studies that included risk ratios or odds
ratios (ORs) for acute MI, stroke, VTE or pancreatitis
according to CHC use and dyslipidemias (elevated total
cholesterol, LDL, or triglycerides or decreased HDL). We
included all forms of CHCs: pills, transdermal patches, vaginal
rings and injectables. We also examined studies reporting on
both the individual and aggregate effects of dyslipidemia and
CHC use on these outcomes. However, we excluded studies
only reporting risks among healthy users; reports articulatingthe risk forMI, stroke, VTE or pancreatitis amongwomenwith
known dyslipidemias compared to women without the
condition who were using any of the combined hormonal
methods satisfied the criteria for inclusion in this review. We
also included studies reporting on changes in lipid levels to
determine risk for worsening of existing abnormalities.
Individual case reports, case series and articles investigating
lipid changes among healthy CHC users did not satisfy
inclusion criteria.
2.3. Study quality assessment
The quality of each study was assessed using the system
for grading evidence developed by the United States
Preventive Services Task Force [7]. Evaluation criteria
included study design, sample size and representativeness,
maintenance of comparable groups, extent of loss to follow-up,
completeness of outcome measurements and adjustment for
potential confounders.
2.4. Data synthesis
Evidence was summarized and systematically assessed
using standard abstract forms [8]. Studies were abstracted by
one author (M.D.) and verified by another (K.C.). It was not
possible to compute summary measures of associations due
to the limited evidence identified.3. Results
Of the 306 articles identified by the search strategy, three
satisfied the review inclusion criteria (See Table 1). One case–
control study and one retrospective cohort study provided
direct evidence for the outcomes ofMI, stroke andVTE [9,10].
No studies evaluated the outcome of pancreatitis. One cohort
study evaluated changes in serum lipids among women with
hypercholesterolemia or hypertriglyceridemia using oral
contraception (COC) [11]. No studies reported on outcomes
associated with use of CHC methods other than COC.
A case–control study performed in the Netherlands by
Tanis et al. [9] evaluated risk of MI among COC users
compared with nonusers. Eligible cases were women, ages 18
to 49 years, admitted to 1 of 16 hospitals for a first MI between
January 1990 and October 1995, identified by International
Classification of Diseases, Ninth Revision (ICD-9) discharge
diagnoses. Eligible controls were women of the same age
range with no history of coronary, cerebral or peripheral artery
disease contacted and screened for participation via random
digit dialing. Eighty-five percent of potential cases identified
(n=285) and 73% of potential controls (n=925) agreed to study
participation. All women were asked to complete a mailed
questionnaire requesting information about demographics,
reproductive history, contraceptive use and various risk factors
for cardiovascular disease. Photographs of available contra-
ceptive formulations [≤30 mcg EE plus lynestrentol, north-
indrone, levonorgestrel, desogestrel or gestodene] were
282 M. Dragoman et al. / Contraception 94 (2016) 280–287provided to aid women in recall of COC use. Women were
determined to have hypercholesterolemia if they reported
diagnosis by a physician and/or reported treatment for the
condition prior to the index date. Compared with non-COC
users without hypercholesterolemia, women with hypercholes-
terolemia but noCOC use had an increased risk ofMI (adjusted
OR [adj OR] 3.3, 95% confidence interval [CI] 1.6–6.8), as did
womenwho used COCs but did not have hypercholesterolemia
(adj OR 2.0, 95% CI 1.4–2.8). However, women with both
COC use and hypercholesterolemia had a much higher
magnitude of increased risk of MI compared with women
with neither risk factor (adj OR 24.7, 95% CI 5.6–108.5). ORs
were adjusted for age, area of residence and calendar year.
Investigators from Israel retrospectively identified women
using various combined COC recorded in a large, administra-
tive database. Gronich et al. [10] investigated exposure to a
number of risk factors, including hyperlipidemia, and associ-
ated risks for VTE and transient ischemic attack (TIA) or
cerebrovascular accident (CVA) in this cohort. Women
between the ages of 12 and 50 years were defined as COC
users if they received at least one prescription for COC between
January 2002 and December 2008. A total of 329,995 women
with 431,223 COC use episodes and 819,749 woman-years of
follow-up contributed data to the study. COC exposure was
considered to be a prescription for COCs in the 6 months prior
to the event. Reported outcomes included first episode of VTE,
including deep vein thrombosis (DVT) and pulmonary
embolus (PE), or a TIA or CVA at any network primary care
or hospital facility, identified by ICD-9 diagnosis codes.
Womenwith hyperlipidemia had ICD-9 codes for the condition
noted in the computerized database prior to any thrombotic
event (cases) or at any time until the end of the study period for
women without an event (controls). Among COC users,
women with hyperlipidemia were at increased risk for TIA and
CVA [risk ratio (RR) 1.76, 95% CI 1.51–2.06] and VTE (RR
1.39, 95% CI 1.04–1.85) compared with women without
the condition in univariate analysis; no multivariable analysis
was reported.
Within a large, noncomparative open-labelmulticenter study
of 59,701 women using a COC containing 30 mcg of EE and
250 mcg of norgestimate, Runnebaum et al. [11] sampled 3000
women for nonrandom testing of serum cholesterol and
triglyceride levels at baseline and after 3 and 6 cycles of COC
treatment. Twenty-five percent of over 750 women with
abnormally elevated total cholesterol (≥5.2 mmol/L) and
28% of 500 women with elevated serum triglycerides
(≥1.7 mmol/L) at baseline had normal results (total
cholesterolb5.2 mmol/L; triglyceridesb1.7 mmol/L) after 6
cycles of COC use. Three-quarters of women in both
groups with abnormal results at baseline had persistently
abnormal results at the end of the study. The investigators
also reported observed changes in lipid levels among
healthy COC users. Among 2187 women with normal
cholesterol and 2075 women with normal triglycerides at
baseline, 95% and 96% continued to have normal levels at
the end of the study period.4. Discussion
4.1. MI, stroke and VTE
Two observational studies of poor quality provided direct
evidence for clinical outcomes of MI, stroke, and VTE
among COC users. Tanis et al. [9] reported a significantly
elevated risk for MI among COC users with hypercholes-
terolemia compared with nonusers without hypercholester-
olemia; this increased OR for the joint effects of COC use
and hypercholesterolemia on risk for MI appear to be greater
than what would have been expected from the ORs for either
COC use or hypercholesterolemia alone. However, this
estimate was based on a very small sample of women with
both of these exposures. The study by Gronich et al. [10]
reported that among COC users, those with hyperlipidemia
had a small increased crude risk of stroke and VTE compared
to women without the condition. Given the small magnitude
of the ORs and the questionable quality of this observational
study, the reported risk estimates probably represent only
minimal, if any, true risk for VTE or stroke.
While both studies were national population-based multi-
center investigations, a number of additional methodological
flaws limit interpretation of the results. Neither study clearly
defined the severity or duration of the condition (hypercho-
lesterolemia or dyslipidemias), or the proportion of women
undergoingmedical management and effects of treatment over
time, all potentially impacting risk for arterial and venous
thrombotic events. Baseline characteristics of womenwith and
without lipid abnormalities were not available for comparison.
There was no adjustment for a number of coexisting
cardiovascular risk factors reported as present in the overall
sample populations; examples include smoking, hypertension,
diabetes, thrombophilia and family history.
Both studies evaluated women using modern formulations of
COC containing ≤35 mcg of EE: however, methods to
determine COC exposure may not have adequately measured
COC use at the time ofMI, stroke or VTE. The study by Tanis et
al. [9] examiningMI relied on self-report of COCuse and did not
report the mean time between the index date and questionnaire
completion for cases and controls, both of which may have
introduced recall bias. “Current use” was defined as COC use
within the month of the event; participants were classified as
current, former or never users, but no estimation of duration of
COC use prior to MI was reported. The study examining VTE
and TIA/CVA by Gronich et al. [10] relied on prescription data
to assess COC use. Prescription data may reflect an intention to
use a medication, but may not accurately depict actual use at the
time of the event [12]. Moreover, events attributable to COC
exposurewere defined as any eventwithin 6months of receipt of
a 3-month COC prescription; overestimates of COC exposure
may increase relative risks of VTE or TIA/CVA among users.
Both studies relied on ICD-9 discharge diagnoses to identify
women with MI, TIA and CVA or VTE. One investigator
reviewed all eligible medical records of women with MI; only
those cases with documented presence of symptoms, elevated
cardiac enzyme levels and electrocardiographic changes were
Table 1
Evidence for the safety of combined hormonal contraception use among women with dyslipidemias.
Author, Date, 
Funding, 
Location
Study Design, 
Study Period
Study population Outcome/ 
Method
Results/Outcomes Strengths/Weaknesses Quality
Tanis et al., 
2001[9]
Netherlands 
Heart 
Foundation
The 
Netherlands
Case-control
Jan 1990– 
October 1995
Cases = 248
Controls = 925
Cases were women, 
ages 18 to 49, 
hospitalized for first 
myocardial infarction 
identified by ICD-9 
codes
Controls were women 
ages 18 to 49, identified 
by random digit dialing 
and eligible if no 
history of coronary, 
cerebral or peripheral 
artery disease
MI
Various 
COCs,
EE ≤ 30 mcg 
Cases Controls Adj OR
(95% CI)
COC non-use N=146 N=568
Hypercholesterolemia
No 129 547 Ref
Yes 17 20 3.3 (1.6-6.8)
COC use N=99 N=348
Hypercholesterolemia
No 88 344 2.0 (1.4-2.8)
Yes 11 3 24.7 (5.6-108.5)
OR adjusted for age, area of residence and calendar year
Strengths
Multi-center national study
Included pill users with 
similar estrogen dose
Reported objective criteria 
for MI 
Weaknesses
+/- hypercholesterolemia 
based on self-report; no 
report of severity or degree 
of control with therapy 
OR based on small number 
of women with 
hypercholesterolemia using 
COCs; wide CI
No report of baseline 
characteristics.
No adjustment for other  
cardiovascular risk factors 
(smoking, hypertension, 
diabetes, obesity, or 
thrombophilia mutations)
II-2, 
poor
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with TIA or CVA and VTE with ICD-9 codes, but specified no
further criteria to define outcomes or validate diagnosis codes.
Combining TIA and CVAmay also prove problematic. Though
TIA is an important risk factor for future stroke, women with
TIA experience transient neurologic symptoms without evi-
dence of acute infarction, whereas CVA relates to cerebral
infarction, a muchmore severe outcome [13]. Depending on the
proportions of women with these conditions, the reported
combined risk for TIA and CVAmay overestimate the true risk
forCVAduringCOCexposure amongwomenwith andwithout
dyslipidemia. Further, no distinction was made between
hemorrhagic and ischemic strokes, clinically distinct entities
with different pathophysiologic mechanisms [14].
Given the severe limitations of these data, it is difficult to
draw conclusions about the true risk of MI, stroke or VTE
among CHC users with dyslipidemia. However, the existing
evidence suggests thatwomenwith dyslipidemia usingCHCare
at an increased risk of MI and stroke; only a weak association
between dyslipidemia, CHCuse and risk forVTEwas observed.
4.2. Pancreatitis
As we did not identify any direct evidence on the risk for
pancreatitis among CHC users with dyslipidemia (emphasizingrisks associated with hypertriglyceridemia), we surveyed
existing evidence on the association between elevated triglyc-
erides and pancreatitis. Hypertriglyceridemia is a well-estab-
lished cause of acute pancreatitis and is the third most common
etiology following gallstone disease and alcohol consumption,
accounting for up to 10% of all cases [5]. Though the exact
pathophysiologic mechanisms of hypertriglyceridemic pancre-
atitis are unclear and the absolute risk of pancreatitis based on
triglyceride levels has not been clearly defined, limited evidence
supports the claim that serum triglyceride levels greater than
1000 mg/dl are necessary to induce pancreatitis [15–20]. A
recently published clinical review suggested that the lifetime
risk of pancreatitis among individuals with triglyceride levels
N1000 mg/dl is similar to or slightly higher than the risk
associated with heavy alcohol consumption (approximately
5%) and increases with increasing severity, quoting a risk of
10% to 20% with triglyceride levels N2000 mg/dl [15].
We did not identify any comparative studies evaluating the
risk of pancreatitis among women of reproductive age using
CHC. Two case reports from Germany and the Netherlands
described women with familial hyperchylomicronemia who
developed pancreatitis during use of COC [21,22]. Familial
hyperchylomicronemia, a type I hyperlipoproteinemia, is a rare
genetic disorder affecting 1 in 1,000,000 individuals that causes
severe elevations in plasma triglyceride-rich chylomicrons
Author, Date, 
Funding, 
Location
Study Design, 
Study Period
Study population Outcome/ 
Method
Results/Outcomes Strengths/Weaknesses Quality
Gronich et al., 
2011
No external 
funding
Israel
Retrospective
Cohort
January 2002-
December 2008
329, 995 women, ages 
12 to 50 years, with 431 
223 COC use episodes 
and 819, 749 woman-
years of follow -up; 
thrombotic events 
determined by ICD -9 
codes in Clalit primary 
care and hospital 
databases
VTE
Stroke
Various COCs
Hyperlipidemia
W-YE # DVT and PE
(rate per 10,000 
woman-years)
Crude RR
(95% CI)
No 758,616 466 (6.14) Ref
Yes 61,133 52 (8.51) 1.39 (1.04 -1.85)
Hyperlipidemia
W-YE # TIA and CVA
(rate per 10,000 
woman-years)
Crude RR
(95% CI)
No 758,616 437 (5.76) Ref
Yes 61,133 62 (10.14) 1.76 (1.51 -2.06)
WY-E: woman-years exposure
StrengthsLarge, population -
based cohort
Weaknesses
Used prescription data to 
determine exposure; 
prescription data may not 
accurately reflect COC use
“Current use” of COC 
defined as 3-month 
prescription within 6 
months of index date or 
event
No report on type or 
severity of hyperlipidemia 
or medical management and 
degree of control with 
therapy
No report of baseline 
characteristics of women 
with and without condition 
for comparison
No validation of outcome 
diagnosis
No multivariable analysis 
for potential confounding by 
known risk factors
II -2, 
poor
284 M. Dragoman et al. / Contraception 94 (2016) 280–287[23]. In both cases, women were in their mid-20s with baseline
triglyceride levels between 550 to 2655 mg/dl. One woman
using a monophasic pill containing 30 mcg EE and 0.075 mg
gestodene (GTD) developed necrotizing pancreatitis after 6
months of COC use and went on to experience three further
episodes during a subsequent 6 months of continued COC
exposure. In the other case, a woman reported eight hospitaliza-
tions over 3 years for acute pancreatitis during use of a COC
containing 30 mcg EE and 1.50 mg levonorgestrel (LNG), the
first admission occurring after 1 year of use. In both cases,
pancreatitis resolved and did not recur upondiscontinuation of the
COCduring 3 years and 1 year of surveillance.We also identified
four case reports published between 1960 and 1983 of six healthy
women who developed pancreatitis during use of older
formulations of COC containing either mestranol or ≥100 mcg
EE; no baseline serum triglyceride levelswere presented [24–27].
While it is well established that elevated triglyceride
levels are associated with hypertriglyceridemic pancreatitis,
severe hypertriglyceridemia is rare and the estimated risk of
pancreatitis with triglyceride levels ≥1000 mg/dl is
approximately 5%. It is unclear what role CHC use might
play, if any, in the development of pancreatitis among
women with hypertriglycideremia.
4.3. Changes in lipid levels
One poor-quality study of changing lipid levels among
women with dyslipidemia using COC found that while 25%and 28% of women with abnormally elevated total
cholesterol and triglyceride levels at baseline had normal
levels after 6 months of COC use, the majority of women
continued to exhibit abnormal elevations. Most women with
normal serum cholesterol and triglyceride levels at baseline
maintained normal lipid levels throughout the study. This
study suffers a number of limitations. Within a very large
cohort of women (n=59,701) recruited for an open label,
noncomparative study of a single COC formulation, the
authors provide no information on how the subgroup of
women undergoing serum lipid testing is selected. Also, no
information about the baseline characteristics of women with
abnormal and normal lipid profiles was provided for
comparison. The authors used minimum criteria for lipid
disease classifications to present dichotomous results
[28,29]; however, it is not possible to draw meaningful
conclusions about clinically relevant changes in lipid levels
among those women with persistent abnormalities in the
study. In addition, the investigators did not report whether
women who underwent testing were blinded to their results
at baseline. If participants became newly aware of a lipid
abnormality, they may be more likely than women with
normal cholesterol or triglycerides to institute lifestyle
changes that could impact lipid levels over time; in such a
case, the favorable trends observed among women with lipid
abnormalities at baseline could have nothing or very little to
do with COC use. Moreover, without comparison to COC
nonusers with and without dyslipidemia, it is impossible to
Author, Date, 
Funding, 
Location
Study Design, 
Study Period
Study population Outcome/ 
Method
Results/Outcomes Strengths/Weaknesses Quality
Runnebaum et 
al., 1992[11]
Not reported
Not reported
Prospective 
Cohort 
(embedded in 
large, non-
comparative 
study)
6 cycles of 
treatment
Included reproductive 
aged women with 
regular menstruation, 
and no history of VTE, 
CVA or MI or other 
medical 
contraindications for 
COC use
3000 women with 
serum cholesterol and 
triglyceride 
measurements at 
baseline and 6 months
Changes in 
lipid levels
35mcg EE/
250 mcg 
norgestimate
Total cholesterol (n=2943)
Of 756 women with elevated cholesterol levels (> 5.2 mmol/L) at 
baseline, 75% had levels that remained elevated while 25% had 
normal or low cholesterol levels after 6 cycles of COC.
Of 2187 women with total cholesterol levels in normal range (< 5.2 
mmol/L) at baseline, 95% had low or normal levels after 6 cycles 
of COC.
Triglycerides (n=2575)
Of 500 women with elevated triglyceride levels (> 1.7 mmol/L) at 
baseline, 72% still had high levels and 28% had normal levels of 
triglycerides after 6 cycles of COC.
Of 2075 women with normal triglyceride levels (< 1.7 mmol/L) at 
baseline, 96% still had low or normal levels after 6 cycles of COC.
Note: 5.2 mmol/L = 202 mg/dl; 1.7 mmol/L = 151 mg/dl
Strengths
Uses cutpoints consistent 
with minimum classification 
for dyslipidaemia
Weaknesses
No information on how 
women identified for cohort 
from larger, non-
comparative trial
No baseline characteristics 
reported for subgroups
Dichotomous categorization 
of lipid abnormalities 
provides limited 
information for comparisons 
by baseline lipid levels and 
severity of derangement
Presents incomplete 
information for total women 
tested with no report of 
reason for exclusion from 
results
No indication of whether 
woman blinded to results at 
baseline
No non-COC user 
comparison group 
II -2, 
poor
285M. Dragoman et al. / Contraception 94 (2016) 280–287know if these observed changes in lipid levels represent
normal variations over time.
Among healthy women using CHC, effects on lipoprotein
levels vary depending on relative concentrations of EE and
progestogen contained in a given formulation [6]. Generally,
EE tends to decrease LDL and increase both HDL and
triglyceride levels, while progestogens exert antagonistic
effects, resulting in increases in LDL and decreases in HDL
and triglyceride levels [30]. COCs with less androgenic
progestogens demonstrate greater increases in HDL and lesser
elevations in triglyceride levels compared to other formula-
tions [31]. Women using the combined contraceptive vaginal
ring exhibit similar alterations in lipid profiles compared to
women using COC; however, triglyceride levels may be
slightly higher [32]. Transdermal patch users demonstrate
increases in HDL and triglyceride levels along with decreases
in LDL, similar to women using COC formulations with less
androgenic progestogens [33]. Combined injectable contra-
ceptive users experience increases inHDLover time compared
to copper IUD users [34]. Overall, statistically significant
differences in lipid levels appear to be incremental with small
absolute changes from baseline. Lipids are biomarkers, and
though they are correlated with risk for cardiovascular disease,
it is not clear that any of the observed changes in lipid
metabolism demonstrated among healthy women using CHC
translate to clinically significant impacts for development or
worsening of cardiovascular disease among women with
dyslipidemia using these methods [35].5. Conclusion
Limited evidence from poor-quality observational studies
suggests that risk for MI may be elevated among COC users
with known dyslipidemias and that these women may also
have a small, if any, increased risk for VTE and for stroke.
However, the true association between exposure to CHC and
risk for these critical health outcomes is not estimable due to
significant methodological limitations. No evidence was
identified for the outcome of pancreatitis. Finally, the impact
of CHC exposure on the status of known lipid abnormalities
over time, an intermediate marker for disease, is unclear.
Rigorous research is necessary to better determine any risks
for MI, VTE, stroke or pancreatitis among women with
dyslipidemias exposed to CHC. In particular, studies should
include objective measures to better ascertain exposures and
outcomes, for example, the use of laboratory tests to determine
diagnoses. Ideally, information about other potentially con-
founding risk factors such as age, coexistingmedical conditions,
smoking status and use of medical treatment should be
adequately assessed and controlled for in study design and
data analysis. While indirect, documentation of changes in lipid
levels amongwomenwith abnormalities exposed toCHC is also
important to understanding whether these women experience a
worsening of their condition. Rather than referencing a single
clinical threshold, reports ofmore discrete changes, that is,mean
or median changes over time, in relation to baseline severity of
the condition would also be very useful.
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A.1. Concept 1: Combined hormonal contraception
(Contraceptives, Oral[Mesh] OR contraceptives, oral OR
oral contracept* OR COC OR (Contraceptive Agents,
Female[Mesh] AND patch) OR ortho evra OR norelgestromin
OR (Contraceptive Devices, Female[Mesh] AND ring) OR
NuvaRing OR CVR OR (ring AND vagina) OR ((((combin*
AND inject*) AND contracept*) OR ((((once a month OR
monthly) AND inject*) AND contracept*) OR cyclofem OR
lunelle OR mesigyna OR cycloprovera)A.2. Concept 2: Dyslipidemias
(“Cholesterol, LDL”[Mesh] OR “Cholesterol”[Mesh] OR
“Cholesterol, VLDL”[Mesh] OR “Cholesterol, HDL”[Mesh]
OR “Dyslipidemias”[Mesh]) OR “Hyperlipidemias”[Mesh])
OR “Hypertriglyceridemia”[Mesh] OR “LDL”[All fields] OR
“HDL”[All fields]OR “VLDL”[All fields]OR “cholesterol”[All
fields] OR “dyslipid*”[All fields] OR “hyperlipid*”[All fields]
OR “hypercholesterol*”[All fields] OR “hypertriglycerid*”
[All fields])A.3. Concept 3: Cardiovascular disease
((“myocardial infarction”[MeSH Terms] OR (“myocardia-
l”[All Fields] AND “infarction”[All Fields]) OR “myocardial
infarction”[All Fields] OR (“heart”[All Fields] AND “attack”
[All Fields]) OR “heart attack”[All Fields]) OR (“myocardial
infarction”[MeSHTerms] OR (“myocardial”[All Fields] AND
“infarction”[All Fields]) OR “myocardial infarction”[All
Fields])) OR (“cerebrovascular disorders”[MeSH Terms] OR
(“cerebrovascular”[All Fields] AND “disorders”[All Fields])
OR “cerebrovascular disorders”[All Fields]) OR (“stroke”
[MeSH Terms] OR “stroke”[All Fields]) OR (((“brain”[MeSH
Terms] OR “brain”[All Fields]) OR (“cerebrum”[MeSH
Terms] OR “cerebrum”[All Fields] OR “cerebral”[All Fields]
OR “brain”[MeSH Terms] OR “brain”[All Fields])) AND
((“infarction”[MeSH Terms] OR “infarction”[All Fields]) OR
(“ischaemia”[All Fields] OR “ischemia”[MeSH Terms] OR
“ischemia”[All Fields]) OR (“embolism”[MeSH Terms] OR
“embolism”[All Fields]) OR (“thrombosis”[MeSHTerms]OR
“thrombosis”[All Fields])))A.4. Concept 4: Venous thromboembolism
(“venous thrombosis”[MeSH Terms] OR (“venous”[All
Fields] AND “thrombosis”[All Fields]) OR “venous throm-
bosis”[All Fields] OR (“deep”[All Fields] AND “vein”[All
Fields] AND “thrombosis”[All Fields]) OR “deep vein
thrombosis”[All Fields]) OR DVT[All Fields] OR (“venous
thromboembolism”[MeSH Terms] OR (“venous”[All Fields]
AND “thromboembolism”[All Fields]) OR “venous throm-
boembolism”[All Fields]) OR ((“veins”[MeSH Terms] OR
“veins”[All Fields] OR “venous”[All Fields]) AND (“throm-
boembolism”[MeSH Terms] OR “thromboembolism”[All
Fields] OR (“thromboembolic”[All Fields] AND “event”[All
Fields]) OR “thromboembolic event”[All Fields])) ORVTE[All
Fields] OR PE[All Fields] OR (“pulmonary”[All Fields] AND
“embolus”[All Fields]) OR “pulmonary embolus”[All Fields]
A.5. Concept 5: Pancreatitis
“pancreatitis”[Mesh] and “pancreatitis”[All fields]
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